Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Buy" by Analysts

Key Points

• Analysts maintain a bullish outlook: Repligen has a consensus “Buy” rating from 18 analysts, with 12 buys, three strong buys and three holds. The average 12-month price target is $166.43.
• Quarterly results exceeded expectations: Repligen reported adjusted earnings of $0.54 per share versus the $0.45 consensus estimate, while revenue rose 11.9% year over year to $204.13 million.
• Shares remain highly valued: RGEN recently opened at $169.61, near its 12-month high of $188.73, with a market capitalization of $9.57 billion and a price-to-earnings ratio above 232.

Shares of Repligen Corporation (NASDAQ:RGEN - Get Free Report) have been given a consensus rating of "Buy" by the eighteen analysts that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and three have given a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $166.4286.

A number of brokerages have commented on RGEN. Citigroup upgraded shares of Repligen to a "buy" rating in a research note on Tuesday, July 7th. Wolfe Research assumed coverage on shares of Repligen in a report on Tuesday, June 2nd. They set an "outperform" rating and a $145.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Zacks Research upgraded shares of Repligen from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 30th. Finally, Evercore reaffirmed an "outperform" rating and issued a $160.00 price target on shares of Repligen in a research report on Monday, July 6th.

Repligen Trading Down 1.9%

NASDAQ:RGEN opened at $169.61 on Friday. Repligen has a 12 month low of $100.99 and a 12 month high of $188.73. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $9.57 billion, a price-to-earnings ratio of 232.34, a PEG ratio of 3.16 and a beta of 1.05. The firm has a fifty day simple moving average of $155.13 and a two-hundred day simple moving average of $134.02.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts expect that Repligen will post 2.06 EPS for the current fiscal year.

Insider Activity at Repligen

In other news, CFO Jason Garland sold 733 shares of the firm's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Measured Wealth Private Client Group LLC purchased a new position in Repligen during the 3rd quarter worth $29,000. Los Angeles Capital Management LLC bought a new position in shares of Repligen during the fourth quarter valued at about $36,000. Northwestern Mutual Wealth Management Co. purchased a new position in Repligen during the second quarter worth about $52,000. Farther Finance Advisors LLC boosted its holdings in Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 128 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its position in Repligen by 38.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 104 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source